Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4537842 | 0.86 | ALDH1A1 (0.33) | L3MBTL1L3MBTL3ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL4537249 | 0.86 | ALDH1A1 (0.37) | L3MBTL1L3MBTL3ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL26042916 | 0.82 | L3MBTL3 (0.47) | L3MBTL1L3MBTL3ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL574979 | 0.82 | — | — | |
| SCHEMBL302125 | 0.81 | L3MBTL1 (0.38) | L3MBTL1L3MBTL3ALDH1A1HRH3 | |
| SCHEMBL3436969 | 0.79 | L3MBTL1 (0.46) | L3MBTL1L3MBTL3ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL12772837 | 0.79 | L3MBTL3 (0.46) | L3MBTL1L3MBTL3ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL15806955 | 0.78 | ALDH1A1 (0.40) | L3MBTL1L3MBTL3ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL4534766 | 0.78 | ALDH1A1 (0.40) | L3MBTL1L3MBTL3ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL4542912 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423446-B1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | Bayer Pharma AG (DE) | 2020-09-16 | — | — | EP | claimed |
| US-10435396-B2 | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs | BAYER PHARMA AKTIEGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | claimed |
| US-20190071432-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-07 | — | — | US | claimed |
| WO-2015028989-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-03-05 | — | — | WO | claimed |
| EP-3423446-B1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | Bayer Pharma AG (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-10435396-B2 | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs | BAYER PHARMA AKTIEGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | disclosed |
| US-20190071432-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-07 | — | — | US | disclosed |
| WO-2015028989-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-03-05 | — | — | WO | disclosed |
| EP-2318412-B1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20120309747-A1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
| US-8252787-B2 | Protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120010197-A1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2009071691-A2 | OXINDOLE DERIVATIVES AND THE USE THEREOF AS A MEDICATION | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| US-7297792-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | GARLAND STEPHEN | 2006-10-05 | — | — | US | disclosed |
| EP-1131295-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031037-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | ADK, PDXK, GPR119 | L3MBTL1 4857/4885L3MBTL3 4842/4885ALDH1A1 462/4885 |
| US-10435396-B2 | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs | CYP11B2, CYP19A1, CYP11B1 | L3MBTL1 4657/4885L3MBTL3 4580/4885ALDH1A1 433/4885 |
| US-20120010197-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | L3MBTL1 2564/4885L3MBTL3 3189/4885ALDH1A1 3526/4885 |
| US-20120309747-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | L3MBTL1 2564/4885L3MBTL3 3189/4885ALDH1A1 3526/4885 |
| US-20190071432-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | CYP11B2, CYP19A1, CYP11B1 | L3MBTL1 4735/4885L3MBTL3 4685/4885ALDH1A1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.